Actively Recruiting
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
Led by Daiichi Sankyo · Updated on 2025-10-15
50
Participants Needed
28
Research Sites
210 weeks
Total Duration
On this page
Sponsors
D
Daiichi Sankyo
Lead Sponsor
A
AstraZeneca
Collaborating Sponsor
AI-Summary
What this Trial Is About
This open-label, multicenter, rollover study will provide continued treatment for participants deriving benefit from different therapies received in studies sponsored by Daiichi Sankyo, Inc. (DS) or DS/Astra Zeneca (AZ)-sponsored study (eg. DS8201-A-J101, DS8201-A-U201, DS8201-A-U204, DS8201-A-U207, DS8201-A-U303).
CONDITIONS
Official Title
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent form and willingness to follow all study requirements
- Currently enrolled in a Daiichi Sankyo or Daiichi Sankyo/AstraZeneca-sponsored parent study that has ended
- No evidence of disease progression and investigator-assessed clinical benefit from continued treatment with a study drug
You will not qualify if you...
- Any unresolved or ongoing adverse events that require stopping the study drug
- Having been off T-DXd therapy for more than 18 weeks (126 days) between last dose in parent study and start of this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 28 locations
1
Miami Cancer Institute
Miami, Florida, United States, 33176
Actively Recruiting
2
Duke University - Trent Center
Durham, North Carolina, United States, 27710
Actively Recruiting
3
Flinders Medical Center
Bedford Park, Australia, 5042
Active, Not Recruiting
4
Monash Medical Center
Melbourne, Australia, 3168
Withdrawn
5
Grand Hôpital de Charleroi
Charleroi, Belgium, 6000
Actively Recruiting
6
Instituto Aericas
Rio de Janeiro, Brazil
Not Yet Recruiting
7
A.C. Camargo Cancer Center
São Paulo, Brazil
Not Yet Recruiting
8
IBCC Nucleo de Pequisa e Ensino
São Paulo, Brazil
Not Yet Recruiting
9
Institut Gustave Roussy
Villejuif, France, 94805
Actively Recruiting
10
Rabin Medical Center
Petah Tikva, Israel
Active, Not Recruiting
11
Ospedale San Raffaele
Milan, Italy, 20132
Actively Recruiting
12
Istituto Nazionale Tumori Fondazione G. Pascale
Naples, Italy, 80131
Withdrawn
13
National Cancer Center Hospital
Chūō, Japan, 104-0045
Actively Recruiting
14
Kyungpook National University Chilgok Hospital
Daegu, South Korea, 41404
Actively Recruiting
15
National Cancer Center
Gyeonggi-do, South Korea, 10408
Actively Recruiting
16
Seoul National University Bundang Hospital
Gyeonggi-do, South Korea, 13620
Withdrawn
17
Seoul National University Hospital
Jongno-gu, South Korea, 03080
Actively Recruiting
18
Severance Hospital, Yonsei University
Seoul, South Korea, 03722
Actively Recruiting
19
Asan Medical Center
Seoul, South Korea, 05505
Actively Recruiting
20
Samsung Medical Center
Seoul, South Korea, 06351
Actively Recruiting
21
Complejo Hospitalario Universitario A Coruña
A Coruña, Spain, 15006
Actively Recruiting
22
Hospital Universitari Vall d'Hebron
Barcelona, Spain, 08035
Actively Recruiting
23
Hospital Universitari Dexeus
Distrito de Les Corts, Spain, 08028
Not Yet Recruiting
24
ICO l'Hospitalet - Hospital Duran i Reynals
L'Hospitalet de Llobregat, Spain, 08908
Actively Recruiting
25
Hospital Ruber Internacional
Madrid, Spain, 28034
Withdrawn
26
National Cheng Kung University Hospital
Tainan, Taiwan, 704
Withdrawn
27
National Taiwan University Hospital
Taipei, Taiwan, 10002
Withdrawn
28
Royal Surrey County Hospital
Guildford, United Kingdom, GU2 7XX
Withdrawn
Research Team
D
Daiichi Sankyo Contact for Clinical Trial Information
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here